Effect of Childhood Radioiodine Therapy on Salivary Function
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Other Indications, Endocrine, Thyroid Cancer |
| Therapuetic Areas: | Endocrinology, Oncology, Other |
| Healthy: | No |
| Age Range: | 3 - 55 |
| Updated: | 4/2/2016 |
| Start Date: | September 2014 |
| End Date: | September 2016 |
| Contact: | Stephen Huang, MD |
| Email: | Stephen.Huang@childrens.harvard.edu |
| Phone: | 617-355-2452 |
Radioiodine (I-131) therapy for thyroid disease is known to decrease salivary function in
adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The
investigators goals are to answer this question by measuring salivary gland function before
and after I-131 administration in children who receive radioiodine therapy at our hospital
for thyroid disease.
adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The
investigators goals are to answer this question by measuring salivary gland function before
and after I-131 administration in children who receive radioiodine therapy at our hospital
for thyroid disease.
Radioiodine (I-131) therapy for thyroid disease is known to decrease salivary function in
adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The
investigators goals are to answer this question by measuring salivary gland function before
and after I-131 administration in children who receive radioiodine therapy at our hospital
for thyroid disease. We will use a Modified Shirmer Test to measure saliva production and a
questionnaire to evaluation symptoms of xerostomia.
adult patients. The impact of pediatric I-131 exposure on salivary function is unknown. The
investigators goals are to answer this question by measuring salivary gland function before
and after I-131 administration in children who receive radioiodine therapy at our hospital
for thyroid disease. We will use a Modified Shirmer Test to measure saliva production and a
questionnaire to evaluation symptoms of xerostomia.
Inclusion Criteria:
- Patients who have been treated with radioiodine therapy
- Patients who have never received radioiodine therapy (negative control group)
Exclusion Criteria:
- Non-English speaking subjects will be excluded due to our lack of translation support
resources at this time. Of note, participation in our study cannot benefit
participants in any way.
We found this trial at
1
site
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
